首页|沙库巴曲缬沙坦钠片与琥珀酸美托洛尔缓释片联合治疗冠心病合并慢性心力衰竭的疗效及安全性

沙库巴曲缬沙坦钠片与琥珀酸美托洛尔缓释片联合治疗冠心病合并慢性心力衰竭的疗效及安全性

扫码查看
目的 探讨冠心病(CHD)合并慢性心力衰竭(CHF)患者应用沙库巴曲缬沙坦钠片及琥珀酸美托洛尔缓释片的疗效及安全性.方法 选取 2022 年8 月—2023 年3 月本院收治的 60 例冠心病合并慢性心衰患者为研究对象,按照随机数字表法分为对照组和观察组.其中对照组(n=30)给予琥珀酸美托洛尔缓释片,观察组(n=30)给予琥珀酸美托洛尔缓释片及沙库巴曲缬沙坦钠片.比较两组的临床疗效、心功能、N末端脑钠肽前体(NT-proBNP)及不良反应.结果 治疗后,观察组治疗总有效率为 96.67%,高于对照组的 73.33%,差异有统计学意义(P﹤0.05);观察组每搏输出量水平、左心室射血分数水平均高于对照组,左心室舒张末期内径短于对照组,NT-proBNP水平低于对照组,组间差异有统计学意义(P﹤0.05).两组不良反应比较,差异无统计学意义(P﹥0.05).结论 CHD合并CHF患者应用沙库巴曲缬沙坦钠片、琥珀酸美托洛尔缓释片治疗,效果确切,可提升患者的心功能,降低NT-proBNP水平,且较为安全,值得推广.
The Efficacy and Safety of the Combination of Sacubitril Valsartan Sodium Tablets and Metoprolol Succinate Sustained-Release Tablets in the Treatment of Coronary Heart Disease with Chronic Heart Failure
Objective Exploring the efficacy and safety of sacubitril valsartan sodium tablets and metoprolol succinate sustained-release tablets in patients with coronary heart disease(CHD)and chronic heart failure(CHF).Methods Selecting 60 patients with coronary heart disease complicated with chronic heart failure admitted to our hospital from August 2022 to March 2023 as the research subjects,divide into a control group and an observation group according to the random number table method.The control group(n=30)was given metoprolol succinate sustained-release tablets,and the observation group(n=30)was given metoprolol succinate sustained-release tablets and sacubitril valsartan sodium tablets.Clinical efficacy,cardiac function,N-terminal brain natriuretic peptide precursor(NT-proBNP)and adverse effects were compared between the two groups.Results After treatment,the total effective rate of the observation group was 96.67%,which was higher than the control group's 73.33%,the difference between groups was statistically significant(P﹤0.05);the observation group had higher levels of stroke output and left ventricular ejection fraction compared to the control group,the left ventricular end diastolic diameter was shorter than that of the control group,and NT-proBNP level was lower than that in the control group,the differences between groups were statistically significant(P﹤0.05).Comparison of adverse reactions between two groups,there was no statistically significant difference between groups(P﹥0.05).Conclusion Treatment of patients with coronary heart disease combined with chronic heart failure using sacubitril valsartan sodium tablets and metoprolol succinate sustained-release tablets,and the effect was definite,which can help improve the cardiac function and reduce NT-proBNP level,and it is relatively safe and worthy of promotion.

Coronary heart diseaseChronic heart failureSacubitril valsartan sodium tabletsMetoprolol succinate sustained-release tabletsClinical efficacyCardiac functionAdverse effects

赵慧丽

展开 >

曹县人民医院心内科,山东菏泽 274400

冠心病 慢性心力衰竭 沙库巴曲缬沙坦钠片 琥珀酸美托洛尔缓释片 临床疗效 心功能 不良反应

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(1)
  • 10